Lynette Holzbaur bought $353K of Organon & (OGN)
Executed May 6, disclosed May 7, 1 day later.
Over the 21 trading sessions from the disclosed entry session (May 7), the stock returned +0.1% (delay-adjusted); from the execution session (May 6), +0.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
Lynette Holzbaur (SVP and Corporate Controller) filed 2 Form 4 reports in the trailing twelve months (1 purchase, 1 sale), most often in Organon & Co. (OGN). Across 1 priced purchase filing, the average 21-session return was +0.6% from execution and +0.1% from disclosure (delay-adjusted; derived). The largest single filing was $353K of OGN (26,448 sh × $13.35, as filed), executed May 6.
Healthcare · Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe,…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→26,448 sh × $13.35
Exec May 6
Filed May 7 · 5:30 PM ET